Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31121202 | 0.74 | MEN1 (0.54) | MEN1KMT2ADDAH1NOS1CYP1A2 | |
| SCHEMBL10883178 | 0.74 | MEN1 (0.54) | MEN1KMT2ADDAH1NOS1CYP1A2 | |
| SCHEMBL27013269 | 0.73 | KMT2A (0.48) | MEN1KMT2ADDAH1NOS1CYP1A2 | |
| Hydrochloric Acid SCHEMBL10608206 | 0.69 | MEN1 (0.43) | MEN1KMT2ADDAH1NOS1CYP1A2 | |
| SCHEMBL349833 | 0.69 | EHMT2 (0.53) | MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL191955 | 0.68 | MEN1 (1.00) | MEN1KMT2ADDAH1NOS1CYP1A2 | |
| SCHEMBL12905708 | 0.67 | MTNR1A (0.49) | MEN1KMT2AALDH1A1 | |
| SCHEMBL5566559 | 0.67 | MEN1 (0.44) | MEN1KMT2ADDAH1NOS1CYP1A2 | |
| SCHEMBL27726353 | 0.67 | MEN1 (0.50) | MEN1KMT2ADDAH1NOS1CYP1A2 | |
| SCHEMBL1014295 | 0.65 | TSHR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202994-A1 | BIOTIN-AVIDIN CONTROLLED DELIVERY SYSTEMS | DREXEL UNIVERSITY | 2022-06-30 | — | — | US | disclosed |
| US-20170112971-A1 | BIOTIN-AVIDIN CONTROLLED DELIVERY SYSTEMS | DREXEL UNIVERSITY (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112971-A1 | BIOTIN-AVIDIN CONTROLLED DELIVERY SYSTEMS | BTD, HLCS, HMGB1 | MEN1 4056/4885KMT2A 4707/4885DDAH1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.